Scaling AAV5 production from bench to industrial scale
This webinar presents comparative production data across three fixed-bed scales (2.65 m², 33 m², and 333 m²) and outlines a complete scaling strategy from bench-top to large-scale manufacturing for AAV5 production in adherent cells. You’ll see detailed results on metabolites, viral titer, and empty/full capsid ratios, and learn how to translate these findings into a reliable and scalable upstream process.
Explore how triple transfection of adherent HEK293 cells can be applied effectively across scales, and how fixed-bed bioreactor systems enable automated, risk-reduced industrialization of adherent cell manufacturing. Gain practical guidance on moving from R&D to GMP faster – while maintaining control over cost, dose, and speed.
Discover strategies for overcoming common bottlenecks of 2D flatware systems, illustrating how single-use fixed-bed bioreactors can simplify process transfer, reduce variability, and support large-scale viral vector production. Key considerations for choosing the right upstream approach when scaling viral vector processes will also be highlighted, focusing on balancing performance, cost efficiency, and manufacturing agility.
Watch now to learn about:
• Quantitative production data from three fixed-bed scales, including metabolite trends, titers, and empty/full capsid ratios
• See how bench-top results correlate with large-scale outcomes, providing a roadmap for scaling AAV5 manufacturing
• Understand how automated fixed-bed systems reduce process variability and improve yield consistency during industrialization
Learn more about the iCELLis™ single-use fixed-bed bioreactor systems: https://www.cytivalifesciences.com/products/items/icellis-single-use-fixed-bed-bioreactor-systems-p-36959
Explore how triple transfection of adherent HEK293 cells can be applied effectively across scales, and how fixed-bed bioreactor systems enable automated, risk-reduced industrialization of adherent cell manufacturing. Gain practical guidance on moving from R&D to GMP faster – while maintaining control over cost, dose, and speed.
Discover strategies for overcoming common bottlenecks of 2D flatware systems, illustrating how single-use fixed-bed bioreactors can simplify process transfer, reduce variability, and support large-scale viral vector production. Key considerations for choosing the right upstream approach when scaling viral vector processes will also be highlighted, focusing on balancing performance, cost efficiency, and manufacturing agility.
Watch now to learn about:
• Quantitative production data from three fixed-bed scales, including metabolite trends, titers, and empty/full capsid ratios
• See how bench-top results correlate with large-scale outcomes, providing a roadmap for scaling AAV5 manufacturing
• Understand how automated fixed-bed systems reduce process variability and improve yield consistency during industrialization
Learn more about the iCELLis™ single-use fixed-bed bioreactor systems: https://www.cytivalifesciences.com/products/items/icellis-single-use-fixed-bed-bioreactor-systems-p-36959